Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/nuwellis-jumps-47-after-pediatric-aquadex-study-announcement.webp

Nuwellis Jumps 47% After Pediatric Aquadex Study Announcement

TIM BOHEN•UPDATED OCT. 27, 2026, 11:30 AM ET
Reviewed by Jeff Zananiriand Fact-checked by Ben Sturgill

Nuwellis rose 47% after pediatric Aquadex findings supported its proposed expansion to smaller patients.

NUWE Candlestick Chart

Get Free Alerts

Why Nuwellis Stock Jumped 47% Today

Nuwellis Inc. (NASDAQ: NUWE) is up 47% at $4.56 by by early afternoon after announcing pediatric study findings for its fluid-removal system. The company intends to use that evidence to support approval for treating smaller patients. The announcement does not establish regulatory approval or new sales.

What Nuwellis Inc. Does

Nuwellis makes the Aquadex SmartFlow system, which uses ultrafiltration, a treatment that removes excess fluid from blood. The system supports kidney care and fluid management for patients with heart and kidney conditions.

Aquadex Pediatric Study and Label Expansion

The study collected information about 91 pediatric patients receiving care across seven hospitals. Nuwellis plans to use the findings to support a proposed label expansion, meaning a wider approved use, to patients weighing 5 kg and above.

Nuwellis Trading Volume and Float

about 15 million shares traded, many times the usual pace for this hour. NUWE’s float, the shares available for public trading, is about 3.6 million shares. That limited supply can magnify price swings when demand surges.

Quick Financial Overview

Nuwellis is a loss-making micro-cap, meaning a very small publicly traded company, with a market value of $16.6M. It reported $3.9M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026 and used $3.2M in operating cash during the quarter. That covers about four months at that pace.

Nuwellis Revenue and Earnings

Quarterly revenue was $2.0M, while the company reported a net loss of $4.8M. Sales did not cover all costs during that period.

Nuwellis Share Offering Risk

Nuwellis has recent share-offering filings on record. If the company sells more shares to raise cash, existing holders would own a smaller percentage of the company, a risk called dilution.

Get Free Alerts

Nuwellis Stock’s Six-Month Change Is down 99%

NUWE’s sharp longer-term decline puts today’s rebound in context, rather than showing that the slide has ended. Shares moved from around $3.25 to the high $5s by by late morning, and were still above the session low when last checked. For Nuwellis, the last daily move this large was sixty-one sessions ago.

Nuwellis Reverse Split and Share History

Nuwellis has a reverse split in effect, meaning multiple shares are combined into fewer shares without adding value to the business. It can make older price levels harder to compare with today’s share price.

Get Free Alerts

Conclusion

Nuwellis has to raise money unless its cash flow improves, making the next earnings report, listed for Wednesday, important beyond the study results. Stronger results or a clearer funding plan could help sentiment, while weak results or financing pressure could weigh on the stock. An exact report date and the next dated macro event have not been announced in the information available here.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders